Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · IEX Real-Time Price · USD
30.03
-0.76 (-2.47%)
Mar 21, 2023, 4:00 PM EDT - Market closed
-2.47%
Market Cap 1.66B
Revenue (ttm) n/a
Net Income (ttm) -154.81M
Shares Out 55.18M
EPS (ttm) -2.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 239,457
Open 31.18
Previous Close 30.79
Day's Range 29.94 - 31.32
52-Week Range 13.15 - 44.75
Beta 1.76
Analysts Buy
Price Target 56.74 (+88.94%)
Earnings Date May 2, 2023

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-muta... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 21, 2020
Employees 169
Stock Exchange NASDAQ
Ticker Symbol KYMR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56.74, which is an increase of 88.94% from the latest price.

Price Target
$56.74
(88.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small ...

2 weeks ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the ...

3 weeks ago - Zacks Investment Research

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023

3 weeks ago - GlobeNewsWire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences

1 month ago - GlobeNewsWire

X-Chem and Kymera Expand Existing Partnership

WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc....

1 month ago - Business Wire

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel s...

2 months ago - GlobeNewsWire

All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy

Kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel s...

2 months ago - GlobeNewsWire

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m...

2 months ago - GlobeNewsWire

7 Perfect Presents to Gift Your 2023 Stock Portfolio

New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations t...

Other symbols: ADMAMDARRYHBANMRKPRGO
3 months ago - InvestorPlace

Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.

3 months ago - Zacks Investment Research

Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?

What's trending in the pharmaceutical sector today? In a fresh press release, Kymera Therapeutics (NASDAQ: KYMR) disclosed positive results from its clinical trial for a skin condition treatment the ...

3 months ago - InvestorPlace

Kymera's stock rallies as it plans to move treatment into Phase 2 studies next year

Shares of Kymera Therapeutics Inc. KYMR, -7.68% rallied about 35% in premarket trading on Wednesday after the company shared positive data from a Phase 1 clinical trial evaluating the treatment it's d...

3 months ago - Market Watch

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi's Decision to Advance KT-474 into Phase 2 Clinical Trials

KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favor...

3 months ago - GlobeNewsWire

Preclinical Data from Kymera Therapeutics' Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies

3 months ago - GlobeNewsWire

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

3 months ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -12.86% and 41.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

4 months ago - Zacks Investment Research

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial

4 months ago - GlobeNewsWire

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m...

4 months ago - GlobeNewsWire

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences

5 months ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?

Kymera Therapeutics, Inc. (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in ...

5 months ago - Zacks Investment Research

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete

5 months ago - GlobeNewsWire

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333 Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333

6 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming September Conferences

WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m...

7 months ago - GlobeNewsWire